powered by RealWire
Tweet Facebook LinkedIn

30-Second Test Breathes Life Into Your Day

Contacts

Client
George Wright
External Communications Executive
GlaxoSmithKline UK
Mobile +44 (0)7785 432 788
george.w.wright@gsk.com 

Multimedia

Images

MyAsthma Logo
MyAsthma Logo
MyAsthma Home Screen
MyAsthma Home Screen
MyAsthma ACT Test
MyAsthma ACT Test

Featured Video


Rob Horne video: Mike Thomas video:

Share Release

MyAsthma App, A New Dimension In Asthma Control

[London, 10 January 2012] GlaxoSmithKline (GSK) is proud to announce the launch of MyAsthma, the UK’s first, free personalised health application (app) designed to help people over the age of 12 take greater control of their asthma. The app features the Asthma Control Test™ (ACT), a simple 30-second test developed by leading asthma experts, which gives asthma patients a useful measure of their asthma control in an easy-to-understand score. Although many patients are receiving treatment for their asthma, a recent survey in the UK shows that almost 50% do not have their asthma under control.[i] MyAsthma applies new technology to traditional asthma management to provide a daily personalised plan helping patients to manage their asthma more effectively.

MyAsthma is exciting for people with asthma as it uses new technology to help them better understand and control this chronic disease. MyAsthma can also be used by carers of people with asthma, especially parents and is a great way to teach older children the importance of taking control of their asthma. This creates a habit that they can carry into adulthood, a significant and positive step for the future of asthma care in the UK” said Dr Mike Thomas, Asthma UK Senior Research Fellow with the University of Aberdeen. “Empowering patients to take more control of long-term conditions not only leads to improved health outcomes but also cost savings”.

Asthma is a chronic condition of the airways with symptoms including breathing difficulties and sudden episodes of breathlessness.[ii] Asthma affects approximately 5.4 million people in the UK[iii] with 4.3m adults and 1.1m children, currently receiving treatment for mild, moderate or severe asthma.[iii] When not well controlled, asthma symptoms can result in hospitalisation, even fatality. Asthma places a significant economic burden on both individuals and society. The NHS spends around £1 billion a year treating and caring for people with asthma and between 2008 and 2009, up to 1.1 million working days were lost due to breathing or lung problems.[iii]

Designed with the support of a panel of asthma experts and Professor Rob Horne, a behavioural psychologist at the University of London, MyAsthma displays localised information on asthma triggers such as pollen count, pollution and weather. It is enabled to help patients track their symptoms and ACT score evolution over time and contains a library with useful information about asthma. An algorithm generates tailored messages, based on a person’s ACT score and individual profiles, to help people address the personal barriers they face and to help them improve their management of the condition. MyAsthma is convenient and easy to use allowing patients to track their asthma control at the quick touch of a smartphone screen, which can help to create a more informed dialogue during consultations with their healthcare professional.

Are you in control of your asthma? ‘ACT’ now with MyAsthma and visit myasthma.com.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

- ENDS -

NOTES TO EDITORS

About the Asthma Control Test™ (ACT)
‘Asthma control’, a concept used to classify asthma, is a composite measure based on the level of symptoms, lung function status, presence of exacerbations, use of rescue medicine and degree of limitation for normal activities. The ACT is a validated, patient self-assessment tool, to assess the level of asthma control over the last four weeks.

GSK is the Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games. GSK will provide facilities and equipment to enable King’s College London to operate a World Anti-Doping Agency (WADA) accredited laboratory during the Games.

GSK has shared MyAsthma with all Team GB and Paralympics GB athletes with asthma competing in the London 2012 games. Ian McCurdie, Chief Medical Officer, British Olympic Association, said “Many people believe asthma can limit participation in sport, however many Team GB and Paralympics GB athletes have asthma. Their success is proof that asthma control matters. Checking your ACT score is a great way for everyone with asthma, not just top athletes, to check they are in control.”

GSK Disclosure:
Dr Mike Thomas is one of the expert asthma advisors to this programme and he is contracted by GSK to support the development of the MyAsthma initiative.

For further information
Phillipa Wallace
Product Communications Director,
Global R&D and Portfolio Communications
GlaxoSmithKline
Direct Tel +44(0)208 047 5623
Mobile +44 7779 276261
philippa.x.wallace@gsk.com

George Wright
External Communications Executive
GlaxoSmithKline UK
Direct Tel +44 (0)20 8792 2922
Mobile +44 (0)7785 432 788
george.w.wright@gsk.com 

[i] Adamek L et al. Poster presented at ATS 2011.
[ii] National Health Service. Asthma. Last accessed 18 Nov 2011 http://www.nhs.uk/conditions/asthma/Pages/Introduction.aspx
[iii] Asthma UK. For journalists: key facts & statistics. Last accessed on 17 Nov 2011 http://www.asthma.org.uk/news_media/media_resources/for_journalists_key.html